Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Atherosclerosis. 2011 Dec 7;220(2):587–592. doi: 10.1016/j.atherosclerosis.2011.11.038

TABLE 2.

Association of Adiponectin Quartile with Adverse Cardiovascular Outcomes After Adjusting for Prognostic Markers.

HR (95%CI) quartile IV vs. I of adiponectin
Myocardial
Infarction		 P
value		 Heart failure P
value		 Death P
value		 Any event or
death* 		P
value
Model 1a 0.64 (0.38–1.06) 0.08 1.63 (1.04–2.56) 0.03 1.67 (1.24–2.26) 0.008 1.54 (1.31–2.21) 0.002
Model 2b 0.71 (0.43–1.20) 0.2 1.62 (1.02–2.56) 0.04 1.62 (1.19–2.20) 0.002 1.51 (1.14–2.00) 0.004
Model 3c 0.82 (0.46–1.46) 0.51 2.11 (1.27–3.51) 0.004 2.09 (1.50–2.93) <.0001 1.85 (1.36–2.51) <.0001
Model 4d 0.78 (0.39–1.55) 0.48 0.99 (0.48–2.02) 0.97 1.77 (1.12–2.67) 0.007 1.43 (0.98–2.09) 0.06
*

Any event or death is defined as myocardial infarction, heart failure, or death.

a

Model 1 adjusts for Demographics (age, sex, race).

b

Model 2 adjusts for Model 1 + Clinical Risk Factors (diabetes, eGFR, beta-blocker, aspirin, statin).

c

Model 3 adjusts for Model 2 + Metabolic Markers (BMI, Hemogloblin A1c, insulin, glucose, non-HDL cholesterol, HDL, triglycerides).

d

Model 4 adjusts for Model 3 + measures of baseline cardiac disease severity (LV ejection fraction, diastolic dysfunction, inducible ischemia, log CRP, log NT-proBNP).

Abbreviations: eGFR,estimated glomerular filtration rate; BMI, body mass index; HDL, high-density lipoprotein; LV, left ventricular; CRP, C-reactive protein; NT-proBNP, amino terminal fragment of the rohormone of braintype natriuretic peptide.